Clinical Trials
17 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT07044336 2026-05-20
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT06180733 2026-05-01
PAM-II
University Medical Center Groningen
Phase 2 Active not recruiting
NCT07542704 2026-04-21
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
Phase 1 Not yet recruiting
NCT06952660 2026-04-20
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Pfizer
Phase 4 Recruiting
NCT05559879 2026-04-15
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT03555422 2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT07523152 2026-04-13
SAPPHIRE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Not yet recruiting
NCT05990426 2026-03-24
FAST
Northwestern University
Phase NA Recruiting
NCT06662435 2026-03-23
GYNCOG
Northwestern University
Phase NA Completed
NCT04038619 2026-03-20
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07038369 2026-03-17
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
NCT01247779 2026-03-13
ROBO-GYN
Centre Oscar Lambret
Phase NA Completed
NCT05758688 2026-03-12
PROPS GYN
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05677048 2026-03-09
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
Phase NA Active not recruiting